Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CLLS

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts position them for standout growth in the cancer treatment market.

Barchart · Jul 28, 2025

This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?

This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?

Shares of this biotech company have had a rough ride in 2024, but analysts are feeling good about its future.

Barchart · Jan 3, 2025

Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut

Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut

About 14 months after inking a natural killer cell deal with Cellectis SA (NASDAQ:CLLS), Cytovia plans to list on NASDAQ via a merger with the SPAC Isleworth Healthcare Acquisition Corp (NASDAQ:ISLE). The company went on to create a China joint venture. The biotech teamed up with China-based biotech investor TF Capital to form CytoLynx Therapeutics with…

Benzinga · Apr 27, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Cellectis Reveals Preclinical Data On First Allogeneic Dual CAR T-Cell Product In Non-Hodgkin Lymphoma

Cellectis SA (NASDAQ:CLLS) released preclinical data on its product candidate UCART20x22 at the American Association for Cancer Research (AACR) Annual Meeting. The Company said that the data showed preclinical proof of concept with the potential to overcome common mechanisms of resistance to CAR T-cell therapies in relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL),…

Benzinga · Apr 11, 2022

1

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

424,774 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play